Pioglitazone and Quetiapine XR Pharmacogenetic Study

University Hospitals Cleveland Medical Center42 enrolled

Overview

Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bipolar Disorder Major Depressive Disorder

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24 * Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study * Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder * Patient must be at least 18 years old * Patient must be willing to give a blood sample Exclusion Criteria: * Patient lacks the capacity to provide informed consent

Locations (1)

Outcomes

Primary Outcomes

Genetic markers associated with treatment response

Genetic markers in PPARG, 5-HT2A, CYP3A4 and CYP2C8 genes known to be related in the pharmacodynamics and pharmacokinetics of pioglitazone or quetiapine XR will be associated with treatment response.

Time frame: Up to 1.5 years